Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 574 full-time employees. The company went IPO on 2006-04-12. The firm is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. The company is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product.
Follow-Up Questions
What is Gyre Therapeutics Inc (GYRE)'s P/E Ratio?
The P/E ratio of Gyre Therapeutics Inc is 57.0439
Who is the CEO of Gyre Therapeutics Inc?
Dr. Han Ying is the Chief Executive Officer of Gyre Therapeutics Inc, joining the firm since 2023.
What is the price performance of GYRE stock?
The current price of GYRE is $7.11, it has decreased 1.88% in the last trading day.
What are the primary business themes or industries for Gyre Therapeutics Inc?
Gyre Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Gyre Therapeutics Inc market cap?
Gyre Therapeutics Inc's current market cap is $646.0M
Is Gyre Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Gyre Therapeutics Inc, including 2 strong buy, 5 buy, 1 hold, 0 sell, and 2 strong sell
